Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 28Trastuzumab 16Paclitaxel 14Docetaxel 12Cyclophosphamide 11Capecitabine 11Nivolumab 9fludarabine 7Carboplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Cisplatin 6Specimen Handling 5Leucovorin 5Irinotecan 5Injections 5Gemcitabine 5Fluorouracil 5Bevacizumab 5atezolizumab 4aldesleukin 4Taxes 4Ipilimumab 4Fluorodeoxyglucose F18 4Drug Therapy 4Cetuximab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4zanidatamab 3veliparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Adoptive Transfer × Breast × Clear all
NCT05483491 2025-03-30

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Rutgers, The State University of New Jersey

Phase 1 Recruiting
30 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡